Coya Therapeutics, Inc. · NASDAQ:COYA

Coya Therapeutics — Investor Presentation (May 2023)

29 slides from Coya Therapeutics's investor presentation, May 2023

  1. Slide 1: Unleashing the Power of Tregs

    2020 Unleashing the Power of Tregs COYA THERAPEUTICS, INC. NASDAQ: COYA | Investor Presentation May 2023 www.coyatherapeutics.com

  2. Slide 2: Cautionary Note of Forward-Looking Statements and Disclaimers

    Cautionary Note of Forward-Looking Statements and Disclaimers This presentation and the accompanying oral presentation contain “forward-looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward-looking statements incl

  3. Slide 3: Coya Therapeutics' Highlights

    Coya Therapeutics’ Highlights Focused on Regulatory T Strong Early Multiple Near-Term Catalysts Cells (Tregs) Clinical Data (12-18 months) • Most clinically-advanced company • COYA 301 completed PoC IIT study* in • COYA 301 clinical PoC data in Alzheimer’s focused on Treg-modulating therapies Alzhei

  4. Slide 4: Inflammation Plays a Critical Role in Neurodegeneration

    Inflammation Plays a Critical Role in Neurodegeneration Neurodegeneration: Loss of Selective Inflammation in the Nervous System Population of Neurons Healthy Neuron Sick Neuron Dead Neuron Dysfunctional Tregs play central role in inflammation and progression of neurodegeneration Motor neurons Materi

  5. Slide 5: What Are Tregs and How They Are Dysfunctional

    What Are Tregs and How They Are Dysfunctional Tregs are a type of lymphocyte that modulate the body’s immune response The main functions of Tregs are: • Ameliorate inflammatory Healthy Tregs Dysfunctional Tregs mechanisms and reactions Tregs are important anti-inflammatory immune When Tregs become d

  6. Slide 6: Strong Proof-of-Concept Clinical Data

    Strong Proof-of-Concept Clinical Data COYA 302 COYA 302 for for the the Treatment Treatment of of Coya COYA301 301for forthe theTreatment of Alzheimer’s Treatment of Alzheimer’s Amyotrophic Lateral Amyotrophic Lateral Sclerosis* Sclerosis* disease* disease* Open-label academic study in 4 ALS patient

  7. Slide 7: Robust Treg-focused Pipeline

    Robust Treg-focused Pipeline Partnerships / Upcoming Product Type Discovery Preclinical IND-Enabling Phase 1 Phase 2a Phase 2b/3 Collaborations Milestones COYA 302 (Biologic Combination) H1 2023: POC from IIT - clinical Treg-Enhancing / T data release Effector & H2 2023: File IND Phase 2 study Amyot

  8. Slide 8: Coya's Leadership Has Demonstrated Deep Expertise in Biotech

    Coya’s Leadership Has Demonstrated Deep Expertise in Biotech Management Team Howard Berman, Ph.D. Adrian Hepner, M.D., Ph.D. David Snyder Arun Swaminathan, Ph.D. John Centanni Chief Executive Officer & President & Chief Medical Chief Financial Officer & Chief Business Development Vice President Chai

  9. Slide 9: SAB Comprised of Seminal Leadership in Tregs

    SAB Comprised of Seminal Leadership in Tregs Following the discoveries of Dr. Sakaguchi and Dr. Appel, Coya is developing multiple product modalities to enhance the therapeutic Shimon Sakaguchi, MD, PhD Stanley Appel, MD potential of Tregs for the Distinguished Professor at the World Premier Former

  10. Slide 10: Treg Dysfunction Is a Core Driver of Neurodegeneration

    Treg Dysfunction Is a Core Driver of Neurodegeneration Treg dysfunction is associated with ALS disease progression …and is similarly associated in and burden of disease… other neurodegenerative diseases Treg Dysfunction is Associated Treg Dysfunction Plays a Role in Treg Dysfunction Is with ALS Surv

  11. Slide 11: Initial Findings → Diverse Pipeline Addressing Treg Dysfunction

    Initial Findings → Diverse Pipeline Addressing Treg Dysfunction Key Learnings From Two IIT Studies Conducted …Led to the Discovery and Advancement of COYA at Houston Methodist under Dr. Stanley Appel… 300 Series • Treg Cell Therapy was well-tolerated with no Serious Adverse Our initial learnings dem

  12. Slide 12: COYA 301: Proprietary Treg Enhancing Low-Dose IL-2

    COYA 301: Proprietary Treg Enhancing Low-Dose Il-2 Suppresses Adaptive Immunity - Robustly - and Innate Immunity - Modestly Treg Expansion/Suppressive Function Dysfunctional Tregs COYA 301 are associated with neuroinflammation promoted by activated ALS Dysfunctional Treg Functional Tregs T effector

  13. Slide 13: COYA 301: Investigator-Initiated Study in Alzheimer's Disease (AD)

    COYA 301: Investigator-Initiated Study in Alzheimer’s Disease (AD) Overall Study Design • Proof-of-Concept open-label study, conducted at Houston Methodist Hospital • Population: 8 patients with mild-to-moderate AD • Treatment: 4 monthly COYA 301 cycles administered subcutaneously, followed by 2-mon

  14. Slide 14: Enhances Treg Function and Numbers in vivo in AD Patients

    COYA 301 Enhances Treg Function and Numbers in vivo in AD Patients (N=8) Statistically Significant Enhancement Statistically Significant Enhancement of Treg Suppressive Function of Treg Numbers Treatment F/U Treatment F/U 14 * *** * * Mean (SD) Percentage of Tregs (% of CD4) * ** *** *** 100 12 Mean

  15. Slide 15: Significantly Lowers Plasma Proinflammatory Chemokines and Cytokines in AD Patients

    COYA 301 Significantly Lowers Plasma Proinflammatory Chemokines and Cytokines in AD Patients CCL1 Plasma Levels (N=8) CCL2 Plasma Levels (N=8) IL-15 Plasma Levels (N=8) Treatment F/U 600 Treatment F/U 500 Treatment F/U 14 550 ** ** * *** *** * ** *** ** ** * ** 450 12 Mean (SD) Level (pg/mL) Mean (S

  16. Slide 16: Improved or Halted Cognitive Decline in AD Patients

    COYA 301 Improved or Halted Cognitive Decline in AD Patients MMSE Score (N=8) CDR-SB Score (N=8) ADAS-Cog Score (N=8) Treatment F/U 60 8 28 ns ns ** * * 50 * 24 6 Mean (SD) Score 40 Mean (SD) Score Mean (SD) Score 20 30 4 16 20 2 12 10 0 8 0 0 120 168 0 30 60 90 120 168 0 120 168 Study Day Study Day

  17. Slide 17: COYA 301 Safety & Tolerability

    COYA 301 Safety & Tolerability • Overall, COYA 301 was well tolerated. • Most common adverse events (AEs) were mild injection site reactions and mild leukopenia. • All patients completed the study. • No death or other serious AE occurred over the course of the study. 17

  18. Slide 18: COYA 300 Series as a Backbone for Combination Immunotherapy

    COYA 301 as a Backbone for Combination Immunotherapy Activated T effector Cells Activated Macrophages/Microglia Treg Function CTLA4 Ig COYA Shown therapeutic benefit in ALS and numbers 302 patients Cytokine COYA Neurodegenerative Inhibition Autoimmune COYA 301 Subcutaneous + Complement Inhibition 30

  19. Slide 19: COYA 302 Addresses Dysfunctional Tregs and Pro-inflammatory Macrophages

    COYA 302 Addresses Dysfunctional Tregs and Pro-inflammatory Macrophages COYA 302 = Low Dose IL-2 CTLA4-Ig Dysfunctional Tregs Treg Numbers & Suppressive Function + Pro-Inflammatory Macrophages Anti-Inflammatory Macrophages Pro-Inflammatory Macrophages COYA 301 CTLA4 Low Dose Fusion IL-2 Protein Anti

  20. Slide 20: COYA 302: A Novel Approach to the Treatment of Neurodegenerative Diseases

    COYA 302: A Novel Approach to the Treatment of Neurodegenerative Diseases Unique products compared to commercial IL-2 (High Dose Lyophilized Format) or CTLA4-Ig (Orencia) New Indications Ready-to- including ALS, Unique low dose Well-established administer stable Alzheimer's, strength and GMP other N

  21. Slide 21: Current Therapies for ALS Aim to Slow Disease Progression

    Current Therapies for ALS Aim to Slow Disease Progression Many companies have garnered significant value by demonstrating a limited benefit of slowing the rate of ALS progression PRO-ACT ALS Database RELYVRIO Clinical Data2 RADICAVA Clinical Data3 ALSFRS-R Mean Change at Week ALSFRS-R Mean Change at

  22. Slide 22: COYA 302: Open-Label, Single-Arm PoC Clinical Study in ALS Patients (N=4)

    COYA 302: Open-Label, Single-Arm PoC Clinical Study in ALS Patients (N=4) Screening Treatment Period Follow-Up 20 weeks COYA 302 was administered via subcutaneous 8 weeks injection over 48 weeks Screening Assessments Treatment Period Assessments Post-Treatment Assessments ✓ Clinical Labs ✓ Safety an

  23. Slide 23: COYA 302: Patients' Demographics and Baseline Characteristics

    COYA 302: Patients’ Demographics and Baseline Characteristics ALS Progression Prior to Age Sex Type Onset Baseline Respiratory Status Respiratory Support (years) (ALSFRS-R score) No Respiratory Patient 1 47 Female Familial Limb -1.6 points / month None Insufficiency Respiratory Non-invasive Patient

  24. Slide 24: COYA 302 Appears to Ameliorate ALS Progression Over 48 Weeks

    COYA 302: Appears to Ameliorate ALS Progression Over 48-weeks Mean (±SD) ALSFRS-R Score (N=4) 48 44 33.5 32 30 33.75 40 36 ALSFRS-R Score 32 28 24 20 16 48-Week Treatment Follow-Up 12 n.s. 8 n.s. 4 0 (Weeks) B 4 8 12 16 20 24 28 32 36 40 44 48 52 56 COYA 302 was well tolerated over 48 weeks; the mos

  25. Slide 25: COYA 302: Enhanced Biologic Activity

    COYA 302: Enhanced Biologic Activity Mean (SD) Treg Suppressive Function (N=4) Mean (SD) Percentage of CD4+CD25+FoxP3+ Treg Cells (N=4) CD4+CD25+FoxP3+ Treg Cells (%) 100 Treg Suppressive Function (%) 90 ** ** ** 12 Key Takeaways 80 * 10 70 * 8 60 ✓COYA 302 significantly expands Treg 50 6 suppressiv

  26. Slide 26: COYA 302: Overview of Phase 2 Study Design in ALS

    COYA 302: Overview of Phase 2 Study Design in ALS Study Objectives Main Inclusion Criteria • Efficacy • Diagnosis of sporadic or familial ALS • Safety and tolerability • Time since onset of ALS symptoms ≤ 24 months from Screening • Biological activity • ALSFR-R score ≥ 35 at Screening • Biomarkers •

  27. Slide 27: Total Addressable Market Exceeding $7B

    Total Addressable Market Exceeding $7B US MARKET In the United States Alone: Coya is looking to treat ~1.7mm Estimated 30k people in the US; The global market size is Americans ALS $673mm in 20221 Estimated 60k people in the US; US market size extrapolated to FTD be $600mm2,6 Estimated 1.5 million A

  28. Slide 28: Multiple Near-Term Preclinical and Clinical Catalysts

    Multiple Near-Term Preclinical and Clinical Catalysts H1 2023 H2 2023 2024 • Amyotrophic Lateral Sclerosis PoC IIT data published in peer review journal • Treg biomarker data published in peer review journal • Amyotrophic Lateral Sclerosis PoC IIT data • Enrollment completion COYA 302 presented (MDA

  29. Slide 29: Coya Therapeutics' Highlights

    Coya Therapeutics’ Highlights Focused on Regulatory T Strong Early Multiple Near-Term Catalysts Cells (Tregs) Clinical Data (12-18 months) • Most clinically-advanced company • COYA 301 completed PoC IIT study* in • COYA 301 clinical PoC data in Alzheimer’s focused on Treg-modulating therapies Alzhei

Coya Therapeutics — Investor Presentation (May 2023) on 6ix